Atherosclerosis: Targeting endogenous apo A-I-a new approach for raising HDL

Nature Reviews Cardiology

Volumn 8, Issue 4, 2011, Pages 187-188

  Shah, Prediman K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; APOLIPOPROTEIN A1; CREATININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; QUINAZOLINE DERIVATIVE; RESVERLOGIX; RVX 208; TORCETRAPIB; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; COMPETITIVE INHIBITION; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEART PROTECTION; HUMAN; LIPID OXIDATION; LIPOGENESIS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT OUTCOME;

APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; QUINAZOLINES; RISK FACTORS;

EID: 79953188700     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.37     Document Type: Article

References (10)

1. Nicholls, S. J. et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol. doi:10.1016/j.jacc.2010.11.015.
2. Shah, P K., Kaul, S., Nilsson, J. & Cercek, B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104, 2376-2383 (2001). (Pubitemid 33049524)
3. Shah, P K., Kaul, S., Nilsson, J. & Cercek, B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 104, 2498-2502 (2001). (Pubitemid 33108387)
4. Shah, P K. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr. Opin. Cardiol. 25, 603-608 (2010).
5. Heinecke, J. W. The protein cargo of HDL: mplications for vascular wall biology and therapeutics. J. Clin. Lipidol. 4, 371-375 (2010).
6. Barter, P J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007). (Pubitemid 350146106)
7. Shah, P K. The yin and yang of cholesteryl ester transfer protein in cardiovascular disease. Circulation 120, 2408-2410 (2009).
8. Bailey, D. et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density ipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 55, 2580-2589 (2010).
9. Van der Steeg, W. A. et al. High-density ipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 51, 634-642 (2008).
10. Khera, A. V. et al. Cholesterol efflux capacity high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).